ArticleJournal of industrial microbiology & biotechnology2024
Anti-Parkinsonian 4-hydroxy-2-pyridones from an endolichenic fungus, Tolypocladium sp. (strain CNC14).
Article in Journal of industrial microbiology & biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pyridone alkaloids from an Antarctic endolichenic Tolypocladium sp.Natural products and bioprospecting · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
4-Hydroxy-2-pyridone alkaloids have attracted considerable attention because of their intriguing structures and diverse bioactivities. In our previous study, 4-hydroxy-2-pyridone alkaloids were shown to exhibit potent activity against neuron-associated targets. To discover this class of neuroactive compounds, an array of endolichenic fungal extracts was screened by analyzing liquid chromatography-ultraviolet-mass spectrometry (LC-UV-MS) profiles. The screening yielded strain Tolypocladium sp. (strain CNC14), which produced compounds with characteristic Ultraviolet patterns for 4-hydroxy-2-pyridone alkaloids using our in-house library. Based on these findings, we conducted a chemical investigation, which led to the isolation of four new (1-4) and ten known (5-14) compounds. Their structures were elucidated via spectroscopic methods such as nuclear magnetic resonance and mass spectrometry. The stereochemistry of the new compounds (1-4) was established using rotating frame overhauser effect spectroscopy (ROESY), and the electronic circular dichrosim (ECD) was compared with the calculated data. Interestingly, the side chains of 4-hydroxy-2-pyridone in 1 and 2 were cyclized in different directions to form benzopyrano[3,4-b]pyridinol from previously reported compounds, and all the new compounds were predicted to be biosynthesized from reduced tolypyridone C (7) via the hetero-Diels-Alder reaction. Among the isolated compounds, 4 significantly protected neuronal cells against treatment with 1-methyl-4-phenylpyridinium (MPP+), a Parkinsonian neurotoxin, in an in vitro Parkinson's disease model. One-Sentence Summary: Four new neuroprotective 4-hydroxy-2-pyridone alkaloids were discovered from an endolichenic fungus Tolypocladium sp.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.